Developing the next generation of antibody therapies, Vicero uses our proprietary VINCOBODY technology to build bi- and multi-specific antibodies and antibody drug conjugates with differentiated size, flexibility, and affinity against proven therapeutic targets. Our first focus is immuno-oncology (IO), where our lead program has the potential to address significant remaining unmet need in the IO Solid Tumor Market by maximizing efficacy while limiting immune-related toxicity. We have a plug and play pipeline for additional assets against validated oncology and immunology targets. We have a highly accomplished team with deep drug development experience and proven success bringing blockbuster drugs to the market.